rare hereditary muscle disorders
innovative gene therapy platform
gene-modified muscle cells
skeletal muscle
rare inherited muscle diseases
gene transfer
gene therapy clinical trial
muscle-specific adeno
Rare Diseases'
single gene defects
designed muscle-specific promoters
clinical development
objective of MYOCURE
outcome of MYOCURE
preclinical MTM
diverse family of rare genetic diseases
animal model development
advanced therapy medical product
GSD patients consistent
new therapeutic option
therapeutic proteins
attractive diseases
safer therapeutic vector doses
PHC14 New Therapies
animal models
related preclinical research
glycogen storage disorder
significant morbidity
subsequent toxicology studies
economic valorisation
IRDiRC objectives
dissemination
use of lower
viral vectors
safety
expression
mortality
ATMP
myotubular myopathy
roadmap
Phase
basis
orphan drug designation
undesirable immune reactions
novo
effective cures
current treatment
art
AAV
fold
type
state
scalable manufacturing process
molecular evolution
efficacy
key bottlenecks
relevant stakeholders
diaphragm dysfunction